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ARTICLE
TRAV1-2+ CD8+ T-cells including oligoconal
expansions of MAIT cells are enriched in the
airways in human tuberculosis
Emily B. Wong et al.#
Mucosal-associated invariant T (MAIT) cells typically express a TRAV1-2+ semi-invariant
TCRα that enables recognition of bacterial, mycobacterial, and fungal riboﬂavin metabolites
presented by MR1. MAIT cells are associated with immune control of bacterial and myco-
bacterial infections in murine models. Here, we report that a population of pro-inﬂammatory
TRAV1-2+ CD8+ T cells are present in the airways and lungs of healthy individuals and are
enriched in bronchoalveolar ﬂuid of patients with active pulmonary tuberculosis (TB). High-
throughput T cell receptor analysis reveals oligoclonal expansions of canonical and donor-
unique TRAV1-2+ MAIT-consistent TCRα sequences within this population. Some of these
cells demonstrate MR1-restricted mycobacterial reactivity and phenotypes suggestive of
MAIT cell identity. These ﬁndings demonstrate enrichment of TRAV1-2+ CD8+ T cells with
MAIT or MAIT-like features in the airways during active TB and suggest a role for these cells
in the human pulmonary immune response to Mycobacterium tuberculosis.
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Mucosal-associated invariant T (MAIT) cells are uncon-ventional lymphocytes that use semi-invariant T cellreceptor-alpha (TCRα) chains to recognize non-peptide
small molecule ligands presented by the HLA-Ib molecule MR11–6.
In mice, MAIT cells have been shown to play a protective role in
models of respiratory infection7–10. In humans, MAIT cells are
abundant in the peripheral blood of healthy individuals, where
they produce cytolytic enzymes and pro-inﬂammatory cytokines
and typically express a TRAV1-2+ TCRα chain and the CD8
coreceptor1–4,11–13. MAIT cells are depleted in the blood of
humans with TB4,5,14. However, little is known about the function
and phenotype of MAIT cells in the human lung, especially in the
setting of pulmonary tuberculosis (TB). We postulated that
MAIT cells are recruited to and/or expand at sites where Myco-
bacterium tuberculosis (Mtb) antigens are present, potentially
acting as sentinels of infection in the respiratory mucosa.
Here we report that a population of pro-inﬂammatory TRAV1-
2+ CD8+ T cells are present in the airways and lungs of healthy
individuals and are enriched in bronchoalveolar ﬂuid of patients
with active pulmonary TB. Some of these cells demonstrate MR1-
restricted mycobacterial reactivity, phenotypic features and/or
TCRα chain usage suggestive of MAIT cell identity. We conclude
that TRAV1-2+ CD8+ T cells with MAIT or MAIT-like features
are oligoclonally expanded in the airways during active TB,
suggesting that they play a role in the human pulmonary immune
response to Mycobacterium tuberculosis.
Results
TRAV1-2+ CD8+ T-cells in human lung and intestine tissues.
To explore the role of MAIT cells in healthy mucosal tissues, we
ﬁrst determined the frequency of TRAV1-2+ CD8+ cells in the
respiratory tract of an individual organ donor (Fig. 1a). Dramatic
enrichment was observed in the trachea, where nearly half of all
CD8+ T cells expressed TRAV1-2 (Fig. 1a). TRAV1-2+ cells were
also enriched in the proximal and distal bronchi (35 and 22% of
CD8+ T cells, respectively) and in the lung parenchyma (17% of
CD8+ T cells), relative to the draining mediastinal lymph node
where the frequency (6% of CD8+ T cells) approximated levels
typically found in peripheral blood11,15. To determine the ana-
tomical localization of TRAV1-2+ CD8+ cells in the airway, we
used immunohistochemistry to quantify CD8+ and TRAV1-2+
cells in 1st and 2nd order bronchial sections from three additional
organ donors (Fig. 1b, left). Although the number of CD8+ cells
was similar in tissue sections from the proximal and distal air-
ways, TRAV1-2+ cells were more frequent in the proximal
compared to distal airway (Fig. 1b, right). As expression of
TRAV1-2+ TCRs is insufﬁcient to deﬁne MAIT cells, we also
performed ex vivo functional assays in which cytokine-
production by TRAV1-2+ CD8+ cells upon exposure to HLA
mismatched M. smegmatis-infected antigen-presenting cells is
used to deﬁne mycobacterial-reactive MAIT cells4,12,16,17. In a
single donor for whom paired tissues were available, we evaluated
lymphocytes from lung parenchyma, the small intestinal lamina
propria (LP), and the small intestinal intraepithelial lymphocytes
(IEL) for M. smegmatis-dependent release of the pro-
inﬂammatory cytokine TNF. Interestingly, TNF-producing
TRAV1-2+ cells were found only in the lung (Fig. 1c, left). It is
also notable that CD161, a C-type lectin highly expressed on
peripheral MAIT cells11,13,17, was not detected on TRAV1-2+
CD8+ T cells from the lung but was found in abundance on small
intestinal TRAV1-2+ CD8+ T cells (Fig. 1c, right). We next
compared the frequencies of TRAV1-2+ and TNF-producing
cells in the lung (n= 9) and intestinal mucosa (n= 8, unmatched
samples) where MAIT cells were initially found to be enriched3.
The frequencies of TRAV1-2+ CD8+ T cells were similar across
mucosal sites, associated lymphoid tissues and unmatched per-
ipheral blood samples (n= 6) (Fig. 1d). In contrast, signiﬁcantly
higher frequencies of TRAV1-2+ cells from the lung produced
TNF in response to M. smegmatis-infected cells compared with
TRAV1-2+ cells from lymphoid tissues, small intestine, or per-
ipheral blood (P= 0.035, 0.0025, 0.0023 and 0.0005
(Mann–Whitney U test), Fig. 1e). Cell yields from these tissues
were insufﬁcient to establish functional dependence on MR1
as has been shown previously with this assay4. Nonetheless,
these data demonstrate that mycobacterial stimulation results in
TNF production by donor-unrestricted, lung resident TRAV1-2+
CD8+ T cells.
TRAV1-2+ CDR3α usage in Mtb-infected lung tissue. On the
basis of these results, we hypothesized that pulmonary infection
with Mtb leads to the migration to and/or expansion of TRAV1-2+
CD8+ cells in the lung, potentially driven by Mtb-derived MR1
ligands. A hallmark of the human immune response to Mtb is the
formation of lung granulomas. We therefore sought to determine
the relevance of TRAV1-2+ T cell receptor (TCR) usage in lung
granulomas from patients with TB. Single cell suspensions were
prepared from diseased lung parenchyma from individuals (n= 5)
undergoing clinically indicated surgical resection for complica-
tions of TB18. The most highly diseased lung granuloma (LG)
tissues were designated “A” and the least diseased tissues desig-
nated “C.” CD4- T cells from these samples were sorted by ﬂow
cytometry and subjected to high-throughput repertoire analysis
using the bias-controlled immunoSEQ TCR sequencing plat-
form19. In the 12 samples that yielded the minimal necessary
sequencing data for analysis (>104 productive reads, yielding a
median of 3,919 unique productive TCRα reads (range
397–28,792) and a median of 167 TRAV1-2-utilizing unique
productive TCRα reads (range 19–1081), the overall frequency of
TRAV1-2+ TCR sequences in granulomas ranged from 3.1 to
5.9% across all donors and tissue samples (Fig. 2a and Supple-
mentary Table 1). These frequencies are similar to those observed
in peripheral blood and lymph nodes. We then developed an
algorithm based on published MAIT CDR3α amino acid (aa)
sequences16,20 to determine which of these TRAV1-2+ CDR3α
sequences represented MAIT cell-consistent TCRαs. A CDR3α
sequence similarity analysis was performed using “MAIT Match”
(http://www.cbs.dtu.dk/services/MAIT_Match), a tool based on
the method described by Shen et al.21, where a score of 1 reﬂects a
perfect match and a score of 0 a perfect mismatch with published
MAIT cell CDR3α sequences. To determine the validity of this
tool, we compared the proportion of TRAV1-2+ sequences with
the proportion of TRAV12-2+ sequences (an unrelated control)
for TCRs with scores ranging from 0.85 to 1. MAIT Match scores
of 0.95 to 1 were signiﬁcantly increased among the in TRAV1-2+
but not TRAV12-2+ TCR sequences (P= 0.0035, P= 0.00046, t
test; Fig. 2b). We therefore chose a MAIT Match score of 0.95 as a
conservative threshold to deﬁne MAIT cell-consistent TCRs
(Fig. 2b). In one individual with paired samples from the lung and
mediastinal lymph node (LN), TRAV1-2 usage was comparable at
both sites, but similarity analysis revealed MAIT cell-consistent
TCR enrichment in the lung (P < 0.0001; 2-way ANOVA; Fig. 2c).
To address the possibility that Mtb drives the recruitment and/
or expansion of TRAV1-2+ T cells with MAIT-consistent
CDR3α‘s in granulomatous tissue, we analyzed the MAIT cell-
consistent CDR3α sequences (MAIT Match score 0.95-1) found
in diseased lung parenchyma (n= 5 individuals, 11 samples). It is
established that certain MAIT cell TCRα chains can be shared
among individuals (public sequences)22, while donor-unique
(private) CDR3α sequences can be selected in response to distinct
microbes16. As shown in Fig. 2d, both private and public CDR3α
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sequences were detected among the MAIT cell-consistent CDR3α
sequences present in granulomatous lung tissue isolated from
patients with TB. Notably, public MAIT cell-consistent CDR3α
were frequently encoded by multiple synonymous nucleotide
sequences within individuals suggesting the expansion of multiple
clones with the same CDR3α amino acid sequences (Fig. 2e,
right). In contrast, private MAIT cell-consistent CDR3α
sequences were encoded by individual nucleotide sequences
suggesting that these were the result of expansions of a single
MAIT cell clone in each donor (Fig. 2e, left). Private CDR3α
sequences were not restricted to infrequent clonotypes and in
some tissue samples occurred as the dominant MAIT cell-
consistent TCR.
Bronchoalveolar TRAV1-2+ CD8+ T cells in active pulmonary
TB. Diminished frequencies of circulating MAIT cells have
consistently been observed in people with TB4,5. This apparent
peripheral depletion may occur as a consequence of selective
MAIT cell migration to the lung or may reﬂect increased
host vulnerability to infection with Mtb. Having found that
TRAV1-2+ CD8+ cells are enriched in healthy airways and
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respond to mycobacteria (Fig. 1e)4, we hypothesized that pul-
monary infection with Mtb drives the accumulation and expan-
sion of TRAV1-2+ CD8+ cells in the lung in response to Mtb-
derived MR1 ligands. To address this possibility, we measured the
frequency of TRAV1-2+ CD8+ T cells in bronchoalveolar (BAL)
ﬂuid samples obtained from individuals with untreated, active
pulmonary TB and controls with no evidence of infectious or
inﬂammatory pulmonary disease (Supplementary Table 2). In
BAL ﬂuid, TRAV1-2+ CD8+ T cells were signiﬁcantly enriched
in patients with TB at frequencies approximately 3-fold higher
than controls (P= 0.0022, Mann–Whitney U test, Fig. 3a).
Conversely, in matched peripheral blood samples, TRAV1-2+
CD8+ T cells were signiﬁcantly diminished in patients with TB at
frequencies approximately 2-fold lower compared to healthy
controls (P= 0.0028, Mann–Whitney U test, Fig. 3a). To assess
the functional capacity of TRAV1-2+ CD8+ T cells in the BAL
ﬂuid and matched peripheral blood samples, we utilized α-CD2/
CD3/CD28 beads as a stimulant to trigger responses via the TCR.
Cell yields were insufﬁcient to explore ligand-speciﬁc activation,
which may also be subject to bias arising from compartment-
speciﬁc differences in MR1-expression by antigen-presenting
cells23. MAIT cells have been reported to produce IFN-γ, TNF,
granzymes, granulysin, IL-17 and IL-2224–26. Among these, we
chose to measure TNF, a representative Th1 effector cytokine
essential for immune control of Mtb27 and IL-17, an immuno-
modulatory cytokine reportedly produced in a TCR-independent
manner by MAIT cells28. A signiﬁcantly greater proportion of
TRAV1-2+ CD8+ T cells in BAL ﬂuid produced TNF (median
40%, range 36–91%) compared with TRAV1-2+ CD8+ T cells in
matched peripheral blood samples (median 15%, range 4.7–27%)
(P= 0.004, Mann–Whitney U test, Fig. 3b, c and Supplementary
Fig. 1). In contrast fewer than 1% of TRAV1-2+ CD8+ T cells in
the BAL ﬂuid and only 2% in matched peripheral blood samples
produced IL-17 (Supplementary Fig. 2). We therefore concluded
that TCR triggering of these BAL-resident TRAV1-2+ CD8+
T cells does not evoke IL-17 production, though other mitogenic
or cytokine-associated stimulations may do so. Next, we char-
acterized the phenotype of BAL-resident TRAV1-2+ CD8+
T cells. MAIT cells can be deﬁned in peripheral blood by TRAV1-
2 usage in conjunction with high-level expression of the c-type
lectin CD161, and the di-peptidase CD2613,26. In BAL ﬂuid
obtained from patients with TB, TRAV1-2+ CD8+ T cells
expressed low levels of CD161 compared with peripheral blood
TRAV1-2+ CD8+ T cells (Fig. 3d), which is consistent with the
data from healthy lung tissue (Fig. 1c) and the prior demon-
stration that CD161 can be down-regulated as a result of MAIT
cell activation17,28,29. In contrast, TRAV1-2+ CD8+ T cells in the
BAL ﬂuid more consistently expressed CD26, which is abun-
dantly present on all functional MR1-restricted MAIT cells in
peripheral blood17,24. CD103, the αE integrin associated with
tissue-resident memory T cells30 was expressed variably but
exclusively on BAL TRAV1-2+ CD8+ T cells.
Although TRAV1-2 usage is a deﬁning feature of MAIT cells,
the same gene segment can be expressed by T cells recognizing
mycobacterial ligands presented in the context of HLA-Ia
molecules and CD1b31. On the basis that TRAV1-2+ CD8+
T cells display a surface phenotype suggestive of tissue-resident
MAIT cells in BAL ﬂuid isolated from patients with active TB, we
postulated that the corresponding CDR3α sequences would
provide a molecular signature reﬂecting MAIT cell enrichment
relative to TRAV1-2+ CD8+ T cells in matched peripheral blood
samples. To test this hypothesis, we performed high-throughput
TCR repertoire analysis of TRAV1-2+ CD4− T cells sorted by
ﬂow cytometry from cryopreserved BAL ﬂuid and matched
peripheral blood specimens obtained from three donors with
active TB (Supplementary Table 3). MAIT cell-consistent CDR3α
sequences comprised a higher percentage of the TRAV1-2+
repertoire in BAL ﬂuid compared with peripheral blood,
irrespective of the parameter used to deﬁne MAIT cell-
consistent CDR3α sequences, including assessment of similarity
to published MAIT cell CDR3α sequences (MAIT Match score=
0.95 or 1) or according to usage of TRAJ12, TRAJ20 or TRAJ33
(Fig. 3e; P= 0.0036; 2-way ANOVA). Among the patients with
TB, CDR3α sequences with the highest MAIT Match scores
(≥0.95) were enriched in BAL ﬂuid, while those with the lowest
MAIT Match scores (<0.85), were more frequent in peripheral
blood (Fig. 3f ).
To determine the extent to which individual MAIT cell-
consistent CDR3α sequences (MAIT Match Score ≥0.95) were
shared between these two anatomical compartments, we created a
TCR Enrichment Analysis (TEA) webtool (https://github.com/
eisascience/Wong-Gold-Lewinsohn) to enable visualization and
weighted frequency analysis of the most common MAIT cell-
consistent CDR3α sequences in matched samples (Fig. 3g and
Supplementary Table 4). In all three patients, the most frequent
MAIT cell-consistent CDR3α sequences were present in both
compartments, with disproportionate expansion in the BAL ﬂuid
compared with the peripheral blood. In contrast, CDR3α
sequences with low MAIT Match scores (<0.85) were generally
expanded only in one anatomical compartment (Supplementary
Fig. 3). The selective expansion of MAIT cell-consistent CDR3α
sequences in the lung compartment relative to peripheral blood
suggests antigen-driven clonal expansion in response to pulmon-
ary infection with Mtb.
To determine if TRAV1-2+ CD8+ T cells present in BAL ﬂuid
contained MAIT cells, we examined the MR1-restricted function
of T cell clones generated from a BAL ﬂuid sample obtained from
a patient with TB. Six of these TRAV1-2+ clones (D0033-A1, A2,
Fig. 1 TRAV1-2+ CD8+ T cells from the lung but not the intestine of healthy organ donors respond to mycobacterial infection by producing TNF. a Dot plots
showing the frequency of TRAV1-2+ CD8+ T cells among live CD3+ cells in the indicated tissue samples from one donor. b Tissue sections from the 1st
and 2nd order bronchi were obtained from healthy individuals (n= 3 biologically independent samples). Immunohistochemistry was performed to quantify
CD8+ (median 1.6 × 104 vs. 2 × 104 cells /mm3) and TRAV1-2+ cells (7,000 vs. 4,000 cells/mm3, Supplementary Data). Representative sections from 1st
and 2nd order bronchi are depicted (left), showing CD8+ cells (red), TRAV1-2+ cells (green) and cell nuclei (DAPI; blue). c Histograms depicting TNF
production (left) and CD161 expression (right) by TRAV1-2+ CD8+ T cells from matched lung parenchyma (green), small intestine lamina propria (LP;
blue) and the small intestinal intraepithelial layer (IEL; violet) after overnight stimulation with M. smegmatis-infected antigen-presenting cells (dotted black
line indicates the unstimulated control). d Frequency of TRAV1-2+ cells among CD8+ T cells from lung (n= 9 biologically independent samples),
mediastinal lymph node (Med LN; n= 11 biologically independent samples), IEL (n= 7 biologically independent samples), LP (n= 8 biologically
independent samples), mesenteric lymph node (Mes LN, n= 5 biologically independent samples), and peripheral blood (PBMC; n= 6 biologically
independent samples, Supplementary Data). Medians and interquartile ranges are displayed. e Frequency of TNF-producing TRAV1-2+ CD8+ T cells after
exposure to M. smegmatis-infected antigen-presenting cells: lung (n= 7 biologically independent samples), Med LN (n= 6 biologically independent
samples), IEL (n= 5 biologically independent samples), LP (n= 6 biologically independent samples), Mes LN (n= 2 biologically independent samples),
PBMC (n= 12 biologically independent samples, Supplementary Data). From top to bottom, P= 0.035, 0.0025, 0.0023 and 0.0005 (Mann–Whitney U
test). Medians and interquartile ranges are displayed
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A3, A6, A8 and A10) expressed MAIT cell-consistent CDR3α
sequences (MAIT Match score= 0.98-1; Table 1). Stimulation of
these clones with HLA-mismatched M. smegmatis-infected or
Mtb-infected antigen-presenting cells induced robust IFN-γ,
while two control clones from the same patient (D0033-D7 and
E7) failed to produce IFNγ under identical conditions. In
contrast, stimulation of the TRAV1-2+ clones with HLA-
mismatched M. smegmatis-infected or Mtb-infected MR1-KO
antigen-presenting cells32 resulted in negligible IFN-γ-produc-
tion, thereby demonstrating MR1-dependent cytokine production
consistent with MAIT cell function (Fig. 3h).
MR1 tetramer loaded with 5-OP-RU ligand has been shown to
identify functional MAIT cells in the human peripheral
circulation13. To evaluate whether TRAV1-2+ CD8+ T cells in
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the BAL of humans with TB could be stained by MR1/5-OP-RU
tetramer, as well as the relationship between MAIT cell-consistent
CDR3α usage and MR1/5-OP-RU tetramer staining, we took
advantage of two donors with TB with available cryopreserved
specimens. We stained cells from paired BAL and peripheral
blood samples with TRAV1-2 antibody, MR1/5-OP-RU tetramer
and MR1/6-FP tetramer (negative control). As shown in Fig. 4a,
BAL cells from donor 1020 demonstrated MR1/5-OP-RU
tetramer staining of 33.7% of the TRAV1-2+ cells, supporting
the TCRα sequencing analysis that found that 40.7% of BAL
TRAV1-2 CDR3α sequences were MAIT cell-consistent (MAIT
Match score >.95). In the peripheral blood of this participant,
only 3.06% of the TRAV1-2+ peripheral cells demonstrated MR1/
5-OP-RU tetramer staining, in line with the TCRα sequencing
analysis that had found that 5.09% of peripheral TRAV1-2
CDR3α‘s were MAIT cell-consistent.
In contrast to MR1/5-OP-RU tetramer staining in the
peripheral blood where positive and negative populations were
clearly discernable, the MR1/5-OP-RU tetramer staining of BAL
cells was of heterogeneous intensity and did not allow
unambiguous delineation of MR1/5-OP-RU tetramer negative
and positive populations. As a result, we sorted TRAV1-2+ cells
based on MR1/5-OP-RU tetramer staining, subjected both
positive and negative subsets to TCR sequencing, and analyzed
MAIT cell-consistent CDR3α usage in each population (Table 2).
CDR3α chain sequencing of MR1/5-OP-RU tetramer positive
cells from BAL and peripheral blood revealed that 93.9% and
89.2% of these respectively utilized MAIT cell-consistent TCRs.
CDR3α chain sequencing of the MR1/5-OP-RU tetramer negative
TRAV1-2+ populations demonstrated that a substantial propor-
tion (13.7%) of the MR1/5-OP-RU tetramer negative cells in the
BAL utilized MAIT cell-consistent CDR3α chains. In contrast,
only 2.7% of MR1/5-OP-RU tetramer negative cells from the
peripheral blood utilized MAIT cell-consistent CDR3α chains.
These data suggest that MR1/5-OP-RU tetramer may perform
less efﬁciently in BAL ﬂuid than in peripheral blood. Notably, in
the other donor (91), in whom 28.5% of the TRAV1-2+ cells had
a MAIT cell-consistent CDR3α, only 5.09% of the TRAV1-2+
cells from the BAL stained MR1/5-OP-RU positive. In this donor,
24.7% of the MR1/5-OP-RU tetramer negative cells had MAIT
cell-consistent CDR3α chains, suggesting that MR1/5-OP-RU
tetramer staining of BAL cells may underestimate the presence of
MAIT cells as determined by CDR3α usage.
To better understand the relationship between MR1/5-OP-RU
tetramer staining, CDR3α usage and MR1-dependent T cell
activity, we sorted MR1/5-OP-RU positive cells from the BAL of
an available individual with non-TB pneumonia and performed
limiting dilution cloning using anti-CD3 and IL-2 stimulation.
Following rapid expansion33, each clone was characterized
functionally for MR1-restriction and antigenic speciﬁcity. As
shown in Fig. 4c, four clones (D1004-B3, E1, E5, and H3)
produced IFN-γ when stimulated with M. smegmatis-infected
antigen-presenting cells (A549) and abrogated IFN-γ production
when stimulated with identically infected MR1-KO antigen-
presenting cells32. TCR sequencing demonstrated that each of
these clones utilized a MAIT cell-consistent CDR3α (Fig. 4b).
Surprisingly, despite clear evidence of MR-1 restricted function,
usage of MAIT cell-consistent CDR3αʼs (Table 3) and TRAV1-2
staining of similar intensity (Fig. 4c), these clones demonstrated
considerable heterogeneity in MR1/5-OP-RU tetramer staining,
with two of the four clones staining weakly (Fig. 4d).
Discussion
Collectively, our data indicate that donor-unrestricted myco-
bacterial-reactive TRAV1-2+ CD8+ T cells are present in the
human respiratory mucosa and that pulmonary infection with
Mtb leads to an enrichment of airway resident, pro-inﬂammatory
TRAV1-2+ CD8+ cells including oligoclonal expansions of
MAIT cells.
In lung tissue explanted from healthy organ donors, we ﬁnd
that TRAV1-2+ CD8+ T cells localize to the respiratory tract
mucosal surface. In contrast to their counterparts in the gut
mucosa, TRAV1-2+ CD8+ T cells from the respiratory mucosa
produce TNF in response to mycobacterial stimulation by
donor-unrestricted antigen-presenting cells. This suggests that
TRAV1-2+ CD8+ T cells in the airway mucosa may play a role
in anti-Mtb immunity by initiating a local pro-inﬂammatory
response upon exposure to aerosolized Mtb.
In the setting of active pulmonary tuberculosis, we observed
striking expansions of TRAV1-2+ CD8+ T cells in the bronch-
oalveolar compartment. Compared to paired peripheral blood
TRAV1-2+ CD8+ T cells, the bronchoalveolar TRAV1-2+ CD8+
T cells produced signiﬁcantly more TNF. Some, but not all, of
these expanded bronchoalveolar TRAV1-2+ CD8+ T cells could
be identiﬁed as MAIT cells based on their utilization of MAIT
cell-consistent CDR3α chains, demonstration of MR1-restricted
function or selective binding of the MR1/5-OP-RU tetramer. It
should be noted that among the TRAV1-2+ CD8+ T cells that
could not be unequivocally conﬁrmed as MAIT cells we identiﬁed
subpopulations that displayed certain “MAIT-like” features, such
as high-level expression of CD26 or oligoclonal expansions of
TRAV1-2+ TCRα chains with features similar to MAIT cell
CDR3α sequences (incorporation of the TRAJ12, TRAJ20 or
TRAJ33 segments, or the presence of the Tyr95 which is known
to be critical for MAIT cell TCR binding to MR1-restricted
ligands34). Our attempts to clone these populations have been
unsuccessful to date, such that further work will be required to
determine if these TRAV1-2+ CD8+ T cells with “MAIT-like”
features are restricted by MR1. It is also notable that MR1/5-OP-
RU tetramers identiﬁed only a subset of TRAV1-2+ CD8+
T cells with MAIT cell-consistent CDR3a’s.
We postulate that variable MR1-tetramer staining observed on
bronchoalveolar TRAV1-2+ CD8+ cells could reﬂect a state of
Fig. 2 Expansions of MAIT cell-consistent CDR3α‘s are present in tuberculous lung granulomas. a Frequency of TRAV1-2+ sequences as a percentage of all
productive TCRα sequences. In some cases, multiple areas of tissue were sampled, ranging from closest (A) to furthest (C) from the site of disease.
b MAIT cell TCRα sequences are consistent with similarity scores of 0.95 and 1. Each symbol represents the frequency of TRAV1-2+ or TRAV12-2+
sequences within each similarity score for each donor sample (n= 12 biologically independent samples). c Frequency of total TRAV1-2+ sequences or
those with similarity scores of 0.95 and 1 in the lung (n= 3 biologically independent samples) and mediastinal lymph node (LN, 1 sample) from donor 23.
Height represents mean, error bars represent standard error. d Frequencies among TRAV1-2+ sequences of the top 10 public and private MAIT cell CDR3α
sequences (MAIT Match score ≥0.95) across individual donors and lung samples. e Variation in the number of synonymous nucleotide sequences
encoding the ﬁve most frequent private (left) and public (right) MAIT cell CDR3α amino acid (aa) sequences from all samples displayed in Fig. 3d. For each
aa sequence, each colored bar represents a different nucleotide sequence. The 13 different nucleotide sequences used to generate the shared MAIT cell
CDR3α aa sequence CAVLDSNYQLIW are displayed. Text color represents nucleotide origin: purple (TRAV), black (TRAD or n insertion), red (TRAJ). LG
lung granuloma, LN lymph node. Source data are provided in Supplementary Data
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activation among tissue-resident cells. Supporting this, we note
that differential tetramer staining can be observed following
expansion of MAIT cell clones with activating cytokines (Sup-
plementary Figure 4). Alternatively, we postulate that TRAV1-2+
CD8+ T cells with MAIT cell-consistent CD3α‘s may have altered
tetramer-binding avidity as a result of differential afﬁnity of their
TCRs for MR1-ligands. This possibility is suggested by the vari-
able magnitude of response to M. smegmatis in the functional
assay, and has recently been demonstrated for the photolumazine
I ligand35. Further work will be required to better understand
the relationship between TCR-dependent MR1-dependent
activation, MR1/5-OP-RU tetramer staining, and ligand
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selectivity among bronchoalveolar TRAV1-2+ CD8+ T cells. At
this point we conclude that MR1/5-OP-RU tetramer staining of
bronchoalveolar MAIT cells is weaker and more variable than
MR1/5-OP-RU tetramer staining of peripheral blood MAIT cells
and hence may underestimate MAIT cell prevalence in the BAL.
In contrast to the bronchoalveolar ﬂuid of active TB patients,
analysis of TCRα chain usage in granulomas of patients under-
going lung-resection for clinically complicated tuberculosis did
not demonstrate dramatic expansions of TRAV1-2+TCRαʼs. The
contrast between the enrichment of TRAV1-2+ CD8+ T cells
observed in bronchoalveolar lavage ﬂuid and the relatively low
frequencies of TRAV1-2+TCRα's found in the lung granuloma
tissue may be due to differences between cells present in the
airway mucosal environment and in lung parenchymal tissue. It is
also possible that the kinetics of expansion of TRAV1-2+ CD8+
cells with MAIT cell-consistent CDR3α‘s varied during the long
course of TB disease and anti-tuberculosis therapy that preceded
surgical treatment in these medically-complex lung-resection
patients.
It is therefore notable that even in the resected granuloma
tissue, the subset of TCRα‘s with MAIT cell-consistent sequences
was enriched among the TRAV1-2+ CDR3α‘s in lung granuloma
tissue compared to paired mediastinal lymph node tissue. We
postulate that this relative enrichment of MAIT cell-consistent
TCRs among TRAV1-2+ sequences from the lung was driven by
local antigen exposure, while acknowledging that tissue-speciﬁc
non-antigen stimuli could also lead to the independent expansion
of clones in the lung compartment. Further understanding of this
will require additional organ-speciﬁc datasets to allow compar-
ison of diseased and reference TCR repertoires. We found both
public and private MAT cell-consistent CDR3α chains in the TB-
infected human lung tissues we analyzed. Interestingly, public
MAIT cell-consistent CDR3α chains were frequently encoded by
multiple synonymous nucleotide sequences within an individual
sample. This ﬁnding is consistent with a previous report impli-
cating convergent recombination as a determinative process in
the generation of public MAIT cell CDR3α sequences22, and
suggests that tissue-resident public MAIT cell-consistent CDR3α
expansions are the result of multiple individual MAIT cells
clonally expanding in infected tissues. The signiﬁcance of cells
with private MAIT cell-consistent CDR3α chains in the context of
Mtb-infected tissue remains uncertain. One possibility is that
public and private MAIT cell-consistent CDR3α chains have
similar ligand-binding properties, such that utilization and
expansion of speciﬁc clonotypes in individual hosts is the result of
differences in the naive TCR repertoire and is not driven by
speciﬁc microbial exposures. Alternatively, the observed clonal
expansion of private MAIT cell-consistent clonotypes within
Mtb-infected tissue may reﬂect selective expansions in response
to the local presence of microbe-derived ligands presented by
MR135. A third possibility is that because our sample set is small,
sequences that appear to be private in this analysis could in fact
turn out to be public when larger numbers of individual donors
are sampled. In order to determine the signiﬁcance of private and
Fig. 3 TNF-producing TRAV1-2+ CD8+ cells including oligoclonally expanded MAIT cells are enriched in bronchoalveolar lavage ﬂuid from patients with
TB. a Frequency of TRAV1-2+ cells among CD8+ T cells from the bronchoalveolar lavage (BAL) ﬂuid from patients with TB (n= 6 biologically independent
samples) and cancer controls (n= 6 biologically independent samples), and among CD8+ T cells in matched peripheral blood samples (PBMC) from
patients with TB (n= 5 biologically independent samples) and unmatched peripheral blood samples from healthy controls (n= 13 biologically independent
samples). Medians and interquartile ranges are displayed. **P < 0.01; Mann–Whitney U test. b Dot plots showing TNF production by TRAV1-2+ CD8+
T cells in matched BAL and peripheral blood samples (PBMC) from a patient with TB. Cells were stimulated with α−CD2/CD3/CD28 beads. c Frequency
of TNF or IL-17 production by TRAV1-2+ CD8+ T cells in matched BAL and peripheral blood samples (PBMC; n= 5 biologically independent samples).
Medians and interquartile ranges are displayed. **P < 0.01; Mann–Whitney U test. d Expression of CD161, CD26 and CD103 on TRAV1-2+ CD8+ T cells in
matched BAL and peripheral blood samples (PBMC) from patients with TB (n= 4 biologically independent samples). Histograms are mode-normalized.
e Frequency of MAIT cell-consistent CDR3α sequences within TRAV1-2+ CD4- T cells in BAL ﬂuid and peripheral blood samples (PBMC) from patients
with TB (n= 3 biologically independent samples). Height represents the mean, error bars represent the range. f Relative frequency of CDR3α sequences by
MAIT Match Score category in BAL ﬂuid vs. matched peripheral blood (PBMC; n= 3 biologically independent samples). g Depiction of the top 10 most
frequent MAIT cell-consistent CDR3α sequences (MAIT Match score ≥0.95) among TRAV1-2+ sequences in each compartment. Legend format: CDR3α
aa (# of synonymous nucleotide sequences in peripheral blood, # of synonymous nucleotide sequences in BAL ﬂuid). h IFNγ spot-forming units (SFU)
produced by BAL T cell clones stimulated withM. smegmatis-infected or Mtb-infected wildtype (WT) or MR1-KO A549 cells (n=8 biologically independent
clones). Height represents the mean of two independent replicates per stimulation, error bars represent the standard deviation. Source data are available in
Supplementary Data.
Table 1 TCRα/β sequences and MAIT Match scores for six MAIT cell clones and two control clones derived from
bronchoalveolar ﬂuid from a patient with tuberculosis
Clone TCRα sequencing TCRβ sequencing
TRAV CDR3α TRAJ MAIT Match score TRBV CDR3β TRBJ
MAIT cell clones
D0033-A1 1-2 CAALDSNYQLIW 33 1.00 4-3 CASSQDMVSITDTQY 2-3
D0033-A2 1-2 CAVTDSNYQLIW 33 1.00 3-1 CASSQAETELNTGELF 2-2
D0033-A3 1-2 CVTMDSNYQLIW 33 0.98 6-1 CASSEAGGGYNEQF 2-1
D0033-A6 1-2 CAVVDSNYQLIW 33 1.00 4-2 CASSHSSGTGGNEQF 2-1
D0033-A8 1-2 CVTMDSNYQLIW 33 0.98 6-1 CASSEAGGGYNEQF 2-1
D0033-A10 1-2 CAVTDSNYQLIW 33 1.00 3-1 CASSSGLEVTGELF 2-2
Control T cell clones
D0033-D7 20 CAARFSDGQKLL 16 0.92 7-9 CASSEGTGVEWDGYT 1-2
D0033-E7 39 CAVPGGGADGLT 45 0.85 2 CASVASGVRDTQY 2-3
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Fig. 4 Heterogeneous MR1/5-OP-RU staining of bronchoalveolar TRAV1-2+ CD8+ T cells with MAIT cell-consistent CDR3α‘s and MR1-restricted function.
a Frequency of MR1-tetramer+ cells (loaded with active (5-OP-RU) and control (6FP) ligand) in TRAV1-2+ T cells (gated on live, CD3+, CD8+
lymphocytes) from the BAL ﬂuid and peripheral blood of a patient with TB. The proportion of cells utilizing MAIT cell-consistent CDR3α‘s (MAIT Match
Score ≥.95) in MR1/5-OP-RU tetramer positive and negative populations are shown. b IFNγ spot-forming units (SFU) produced by four T cell clones
generated from BAL ﬂuid and stimulated with M. smegmatis-infected wildtype (WT) or MR1-KO A549 cells, Supplementary Data. c α-TRAV1-2 staining of
four T cell clones generated from BAL ﬂuid demonstrates consistent staining. Histograms are mode-normalized. d Binding of MR1/5-OP-RU tetramer on
the same four T cell clones generated from BAL ﬂuid demonstrates heterogenous MR1/5-OPRU tetramer staining (left). Binding of MR1/6-FP (control) and
MR1/5-OPRU tetramer is shown for two clones (right). Histograms are mode-normalized
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public MAIT cell-consistent TCRs in the context of mycobacterial
infection, further study of selective ligand speciﬁcity in larger
numbers of donors is needed. Nonetheless, the convergence of
multiple nucleotide rearrangements on expanded public MAIT
cell-consistent TCRα chains suggests that in some instances,
multiple MAIT cells with genetically unique but functionally
similar TCRα chains clonally expand in the TB-infected lung,
potentially in response to microbe-derived antigenic-stimulation.
In line with recent studies that have found MAIT cell expan-
sions in the lungs of mice experimentally infected with Mtb36 and
S. enterica serovar Typhimurium (S. Typhimurium)37, we found
expansions of TRAV1-2+ CD8+ T cells with MAIT or MAIT-like
features in the BAL and lung parenchyma in patients with TB.
Supported by the ﬁndings Chen et al. who found that accumu-
lation of MAIT cells in the lungs of mice following challenge with
S. Typhimurium is dependent on antigen derived from the
microbial riboﬂavin synthesis pathway37, we postulate that these
TRAV1-2+ CD8+ cell enrichments contain MAIT cells and are
driven by Mtb-derived small molecular ligands. Howson et al.
recently reported that MAIT cell clones with more avid ligand-
binding expand during S. enterica serovar Paratyphi A infection
and that these clones remain expanded after treatment of the
infection38. This ﬁnding supports the idea that exposure to
microbe-derived MR1 ligands alters the human MAIT cell TCR
repertoire and suggests a role for MR1-ligand vaccine strategies.
Overall our ﬁndings suggest a previously unrecognized and
potentially important role for TRAV1-2+ CD8+ T cells with
MAIT or MAIT-like features in the immune response to aero-
solized Mtb infection, and would support exploration of these
cells as targets of either vaccination or immunotherapeutic
strategy.
Methods
Human subjects. Samples from Portland, Oregon, USA. Airway, lung, small
intestine and associated lymph node tissues ineligible for transplantation were
obtained from the Paciﬁc Northwest Transplant Bank under a protocol approved
by the Institutional Review Board at Oregon Health & Science University. Limited
clinical information was available for these individuals, who were generally con-
sidered healthy prior to demise. For comparison with the organ samples, PBMCs
were obtained by apheresis from healthy adult donors providing informed consent.
Samples from Durban, South Africa. Explanted granulomatous lung tissue and
associated lymph nodes were obtained under a protocol approved by the University
of KwaZulu Natal Human Biomedical Research Ethics Commitee (UKZN BREC)
allowing adults undergoing clinically indicated lung resection for complicated
tuberculosis at Inkosi Albert Luthuli Central Hospital (IALCH) to donate excess
tissue for scientiﬁc research18. Tissue was isolated from different areas of resected
lungs based on the experience of the operating surgeon and the preoperative
radiological data. Clinical characteristics of the individuals and samples have been
described18. All donors provided written informed consent prior to surgery. BAL
ﬂuid and paired peripheral blood samples were obtained under a protocol
approved by the UKZN BREC and Partners Institutional Review Board allowing
collection of excess ﬂuid from adult patients undergoing clinically indicated
diagnostic bronchoscopies at IALCH. Active tuberculosis was deﬁned
microbiologically (positive BAL Mtb culture or BAL Mtb PCR by GeneXpert) and/
or histologically (Ziehl-Neelsen positive necrotizing granulomas on transbronchial
biopsy obtained at the time of BAL). Uninfected controls were deﬁned as
individuals with no evidence of either infectious or inﬂammatory lung disease, as
determined by a committee of study physicians on the basis of clinical history,
chest x-rays, computerized tomography scans, and negative BAL microbiology
(mycobacterial, bacterial and fungal cultures, and Mtb PCR). Most controls
underwent bronchoscopy for suspected lung cancer, and a non-cancerous segment
was lavaged in these cases. All donors provided written informed consent prior to
bronchoscopy. Cryopreserved peripheral blood mononuclear cells (PBMCs) from
healthy donors (deﬁned as asymptomatic and HIV-negative with no evidence of
Mtb by ELISPOT) were available from the iThimba Cohort which was approved by
the UKZN BREC and Partners Institutional Review Board39. All participants
provided written informed consent.
Isolation and stimulation of lung and gut T cells. Lymphocytes were isolated
from fresh lung tissue as described previously4. A two-step process was used to
extract cells from the small intestine. For collection of lymphocytes from the
intraepithelial (IEL) layer, the tissue was washed in HBSS, stripped of muscle, and
incubated with agitation for 30 min in 0.15% dithiothreitol (Sigma-Aldrich). IEL
lymphocytes were then harvested, and the remaining tissue was incubated for 30
min in PBS. Lamina propria (LP) lymphocytes were released by digestion with
0.1% collagenase (CLS-3, Worthington) and 0.3% DNAse (Roche) for 30 min at
37 °C. IEL and LP preparations were further enriched over a discontinuous Percoll
gradient. Lymphocyte stimulations were performed as described previously4,12,16.
Brieﬂy, lymphocytes were incubated for 16 h with uninfected (control) or M.
smegmatis strain mc2122-infected (multiplicity of infection= 3) A549 cells (ATCC
CCL-185) at a ratio of 3:1 in the presence of α-CD28 and α-CD49d (Biolegend),
together with an α-TNF mAb (Beckman Coulter) and the TNF-Processing Inhi-
bitor 0 (TAPI-0, 10 μM) (Calbiochem). Cells were then stained as described above
for surface expression of CD45, CD3, CD8, TRAV1-2, and CD1614. Dead cells
were excluded using Aqua LIVE⁄DEAD (Invitrogen). Stained samples were
acquired on a Fortessa ﬂow cytometer (BD Biosciences) and data were analyzed
with FlowJo software version 10.6 (Tree Star).
Immunohistochemistry of airway tissues. Cryosections (10 µM) of frozen airway
tissues were treated with acetone and air-dried prior to incubation with α-TRAV1-
2 antibody (clone-3C10; Biolegend) followed by goat α-mouse IgG1-Alexa Fluor
488 (1:1000), and then α-CD8 antibody (1:50; LSBio) followed by goat α-mouse
IgG1-Alexa Fluor 568 (1:1000). Sections were washed and stained with DAPI.
Table 2 Comparison of MR1/5-OPRU tetramer staining and usage of MAIT cell-consistent CDR3α sequences within TRAV1-2+
CD8+ T cells in the bronchoalveolar (BAL) and peripheral blood (PBMC) compartments from two patients with active TB
Participant ID Compartment % MAIT cell-
consistent CDR3α
% MR1/5-OPRU
tetramer-positive
% MAIT cell-consistent CDR3α
of MR1/5-OPRU tetramer-
positive
% MAIT cell-consistent CDR3α
of MR1/5-OPRU tetramer-
negative
1020 BAL 40.7 33.7 93.9 13.7
1020 PBMC 5.4 3.1 89.2 2.7
0091 BAL 28.5 5.1 100.0 24.7
0091 PBMC 18.6 6.3 71.4 15.1
Table 3 TCRα/β sequences and MAIT Match scores for four MAIT cell clones derived from bronchoalveolar cells
Clone TCRα sequencing TCRβ sequencing
TRAV CDR3α TRAJ MAIT Match score TRBV CDR3β TRBJ
D1004-B3 1-2 CAVTDSNYQLIW 33 1.00 6-5 CASSYEGGGQPQHF 1-5
D1004-E1 1-2 CAALDSNYQLIW 33 1.00 6-4 CASSDGEGQPQHF 1-5
D1004-E5 1-2 CAAMDSNYQLIW 33 1.00 30-1 CAWSHSDRDLNEQYF 2-7
D1004-H3 1-2 CAAMDSNYQLIW 33 1.00 3 CASSQASGGEETQYF 2-5
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Images were acquired using an Olympus FluoView FV1000 laser scanning confocal
microscope system with a 40 × 1.3 Oil Plan Fluorite objective. Confocal images
were analyzed using Imaris Analysis Software.
Isolation and TCR sequencing of T cells from lung granulomas. Diseased lung
tissue (approximately 3 cm3) was isolated from surgically resected explants. Each
sample was washed in multiple changes of Hank’s Balanced Salt Solution (HBSS),
diced into smaller pieces (approximately 1 mm3), strained, resuspended in pre-
warmed R10 supplemented with 0.5 mg/ml collagenase D (Roche) and 40 U/ml
DNaseI (Roche), and transferred to GentleMACS C-tubes (Miltenyi Biotec) for
mechanical digestion per the manufacturer’s instructions. The resulting suspension
was incubated for 60 min at 37 °C, subjected to an additional mechanical digestion
step, strained through a 70 μm ﬁlter, washed twice in HBSS, and stained prior to
sorting CD4− T-cells using a FACSARIA ﬂow cytometer (BD Biosciences). Cells
were gated as live (nearIR−, Invitrogen), single lymphocytes (determined on the
basis of light scatter), then sorted as CD45+, CD3+, CD4− events directly into RLT
buffer. Genomic DNA was extracted using a DNeasy Minikit (Qiagen) and high-
throughput TCRα sequencing was performed using the ImmunoSEQ assay
(Adaptive Biotechnologies Corp.)40. Data were analyzed using the ImmunoSEQ
Analyser.
CDR3α sequence similarity. Similarity between CDR3α sequences was
calculated as described previously21. This method allows similarities to be
assigned between sequences of different length in an alignment-free manner. An
implementation of the similarity matching between CDR3 sequences is publicly
available at http://www.cbs.dtu.dk/services/MAIT_Match. The server takes as input
a list of CDR3α sequences, and returns for each a score based on the maximal
sequence similarity with a reference database of MAIT cell CDR3α sequences. A
perfect match has a similarity score of 1, and a perfect mismatch a similarity
score of 0.
Collection, staining and stimulation of BAL lymphocytes. Bronchoscopies
were performed by pulmonologists at IALCH. Patients received sedation and
bronchodilators according to the local standard of care; Normal saline (200 mL)
was lavaged into the lobe with the highest burden of pathology or, in patients with
diffuse disease, the right middle lobe. Available BAL ﬂuid was combined in a 1:1
ratio with R10 (RPMI 1640 supplemented with 10% fetal bovine serum, L-gluta-
mine, penicillin and streptomycin) and stored on ice. All samples were
processed within 3 h of collection, BAL ﬂuid was ﬁltered through a 40 µm strainer
(BD Pharmingen) and centrifuged. Resuspended BAL cells were aliquoted for
staining with Aqua LIVE⁄DEAD (Invitrogen) and some or all of the following
antibodies: α-CD3-PE-CF594 (BD Horizon, clone UCHT1), α-CD8-APC-H7 (BD
Pharmingen, clone SK1), α-CD14-PerCP-Cy5.5 (BioLegend, clone HCD14), α-
CD235a-PerCP-Cy5.5 (BioLegend, clone HIR2), α-TRAV1-2-APC (clone OF-
5A1212), α-CD161-PE-Cy7 (BioLegend, clone HP-3G10), α-CD26-PE
(BioLegend, clone BA5b). All stains were performed at 4 °C. Cells were then ﬁxed
with 4% paraformaldehyde. Functional studies were performed if sufﬁcient
numbers of BAL lymphocytes were available. After depletion of macrophages via
plastic adherence for 1 h, 1 × 106 lymphocytes were stimulated for 18 h at 37 °C
with α-CD2/CD3/CD28-loaded Anti-Biotin MACSiBead Particles (Miltenyi Bio-
tec) at a ratio of 2:1 in RPMI 1640 supplemented with 10% fetal bovine serum, L-
glutamine, HEPES, penicillin, and streptomycin. Brefeldin A was added after the
ﬁrst hour to inhibit protein transport from the endoplasmic reticulum.
Stimulated and unstimulated cells were then stained with Aqua LIVE⁄DEAD
(Invitrogen) and the following antibodies: α-CD235a-PerCP-Cy5.5, α-CD14-
PerCP-Cy5.5, α-CD8-APC-H7, α-TRAV1-2-APC, α-CD161-PE-Cy7. After a wash
step, cells were ﬁxed with PERM/FIX Medium A (Invitrogen), permeabilized with
PERM/FIX Medium B (Invitrogen), and stained with the following antibodies: α-
CD3-PE-CF594, α-TNFa-PE (Beckman Coulter, clone IPM2), and α-IL-17-BV421
(BioLegend, clone BL168). Stained samples were acquired using a Fortessa ﬂow
cytometer (BD Bioscience). Rainbow Fluorescent Particles (BD Bioscience) and
applications settings in FACSDiva7 were used to correct for day-to-day
variations in instrument performance. Cells were gated as live (aqua viability dye
negative) lymphocytes (determined on the basis of light scatter), and CD14++ cells
were excluded prior to selecting CD3+ cells for analysis. Paired peripheral blood
samples were collected where possible and freshly isolated PBMC were processed in
parallel with matched BAL cells. Data were analyzed with FlowJo10.6 (Treestar).
Background cytokine production was subtracted to calculate percentage of cells
producing cytokine in response to stimulation. When available, paired cryopre-
served BAL and PBMC cells were thawed and stained with some or all of the above
antibodies and MR1/5-OP-RU or MR1/6-FP tetramers (courtesy of the McCluskey
Laboratory). Cell suspensions were acquired and sorted on a FACSARIA ﬂow
cytometer (BD Biosciences) into TRIzol (Invitrogen). Genomic DNA was extracted
utilizing the phenol-chloroform method according to manufacturer protocol, using
linear acrylamide (Invitrogen) as a carrier. High-throughput TCRα sequencing was
performed using the ImmunoSEQ assay (Adaptive Biotechnologies Corp)40.
Visualization of MAIT cell CDR3α sequences. Data were coded in R using the
packages RColorBrewer, Shiny, data.table, ggplot2, and dplyr. Synonymous
nucleotide sequences within a tissue were counted, and the associated frequencies
are summed. These frequencies were visualized using the TCR Enrichment Ana-
lysis (TEA) webtool the code for which is archived at https://github.com/
eisascience/Wong-Gold-Lewinsohn/tree/v1.0.0
Generation and characterization of T cell clones. Cells from BAL samples were
stained with Aqua LIVE/DEAD (Invitrogen), MR1/5-OP-RU tetramer (0.3 nM,
McCluskey Laboratory), α-CD4-FITC (clone OKT4; BioLegend), and α-CD8-APC-
Cy7 (clone SK8; BioLegend). Live tetramer-binding cells were sorted by the basis of
co-receptor expression using an Inﬂux ﬂow cytometer (BD Biosciences), rested
overnight in RPMI 1640 supplemented with 10% heat-inactivated pooled human
serum and 0.5 ng/ml rhIL-2, and then distributed in limiting dilution format with
irradiated PBMCs (150 × 105/well) and irradiated B-lymphoblastoid cells (3 × 104/
well) in a 96-well round bottom plate. The cultures were stimulated with rhIL-2 (5
ng/ml), rhIL-12 (0.5 ng/ml), rhIL-7 (0.5 ng/ml), rhIL-15 (0.5 ng/ml) and α-CD3
(0.03 µg/ml). Clones were harvested after incubation for 20 days at 37 °C and
assessed for clonality by ﬂow cytometry, TCR sequencing, and MR1-restricted
function by ELISPOT.
Nitrocellulose-backed multiscreen 96-well plates (Millipore) were coated
overnight at 4 °C with a 10 µg/ml solution of α-IFNγ antibody (clone 1-D1K;
Mabtech) in 0.1 M Na2CO3, 0.1 M NaHCO3, pH 9.6. The plate was washed three
times with sterile PBS and blocked for 1 h at room temperature with RPMI 1640
containing 10% heat-inactivated pooled human serum. Uninfected, M. smegmatis
mc2122-infected (multiplicity of infection= 3), or M. tuberculosis H37Rv-infected
(multiplicity of infection= 30) wildtype or MR1-null32 A549 cells (1 × 104/well)
and clonal T cells (1 × 104/well) were added and incubated overnight at 37 °C. The
plates were then washed six times in PBS containing 0.05% Tween-20, incubated
for 2 h at room temperature with a 1 µg/ml solution of α-IFNγ-biotin antibody
(clone 7-B6-1; Mabtech) in PBS containing 0.5% bovine serum albumin and 0.05%
Tween-20, washed again six times in PBS containing 0.05% Tween-20 followed by
PBS alone, and developed using an AEC Vectastain Kit (Vector Laboratories).
Spots were counted using an automated ELISPOT Reader System (Autoimmun
Diagnostika GmbH).
TCR sequence analysis of CD8+ T cell clones isolated from BAL ﬂuid. For
some clones, total RNA was extracted using an RNeasy Mini Kit (Qiagen).
Unbiased ampliﬁcation of all expressed TRA and TRB gene products was then
conducted using a template-switch anchored RT-PCR with chain-speciﬁc constant
region primers41. Amplicons were sub-cloned, sampled, sequenced and analyzed as
described previously42. Gene usage was assigned according to the IMGT nomen-
clature. For other clones, genomic DNA was extracted using a DNeasy Mini Kit
(Qiagen) and high-throughput TCRα and TCRβ sequencing was performed using
the ImmunoSEQ assay (Adaptive Biotechnologies Corp)40. Data were analyzed
using the ImmunoSEQ Analyser.
Statistics and reproducibility. Statistical analyses were performed using Prism 6
(GraphPad Software Inc). The non-parametric Mann–Whitney U test was used to
assess differences between groups unless indicated otherwise. All statistical tests
were two-sided unless indicated otherwise. P values < 0.05 were considered sig-
niﬁcant for direct comparisons. In cases of multiple comparisons the Bonferonni
correction was applied. Experiments were repeated with as many biologically
indpendent samples as were available; when possible a minimum of two experi-
mental replicates were performed.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analyzed during the current study are archived at
https://github.com/eisascience/Wong-Gold-Lewinsohn or available from the
corresponding author on reasonable request.
Code availability
Custom code for the MAIT Match tool is available at http://www.cbs.dtu.dk/services/
MAIT_Match/. Custom code for the visualization of frequencies of speciﬁc TCRα‘s in the
TB granuloma tissues and the TCR Enrichment Analysis (TEA) webtool are archived at
https://github.com/eisascience/Wong-Gold-Lewinsohn
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